Alnylam Pharmaceuticals (ALNY) Capital Expenditures Growth (1y) (2010 - 2026)
Alnylam Pharmaceuticals (ALNY) Capital Expenditures Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 143.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143.40% |
| Dec 31, 2025 | 439.84% |
| Sep 30, 2025 | -156.63% |
| Jun 30, 2025 | 1,312.30% |
| Mar 31, 2025 | 300.09% |
| Dec 31, 2024 | 121.10% |
| Sep 30, 2024 | 41.12% |
| Jun 30, 2024 | -107.41% |
| Mar 31, 2024 | -83.86% |
| Dec 31, 2023 | -165.39% |
| Sep 30, 2023 | 161.58% |
| Jun 30, 2023 | -0.85% |
| Mar 31, 2023 | -22.22% |
| Dec 31, 2022 | 261.18% |
| Sep 30, 2022 | -206.51% |
| Jun 30, 2022 | -24.04% |
| Mar 31, 2022 | 145.01% |
| Dec 31, 2021 | -19.64% |
| Sep 30, 2021 | 109.87% |
| Jun 30, 2021 | -28.73% |